Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 181

1.

Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study.

Carmona-Bayonas A, Jiménez-Fonseca P, Lamarca Á, Barriuso J, Castaño Á, Benavent M, Alonso V, Riesco-Martínez MDC, Alonso-Gordoa T, Custodio A, Sánchez Cánovas M, Hernando Cubero J, López C, Lacasta A, Fernández Montes A, Marazuela M, Crespo G, Escudero P, Diaz JÁ, Feliciangeli E, Gallego J, Llanos M, Segura Á, Vilardell F, Percovich JC, Grande E, Capdevila J, Valle JW, García-Carbonero R.

J Clin Oncol. 2019 Aug 7:JCO1900980. doi: 10.1200/JCO.19.00980. [Epub ahead of print]

PMID:
31390276
2.

Meta-Analysis of Randomized Clinical Trials Comparing Active Treatment with Placebo in Metastatic Neuroendocrine Tumors.

Capdevila J, Hernando J, Perez-Hoyos S, Roman-Gonzalez A, Grande E.

Oncologist. 2019 Jul 22. pii: theoncologist.2018-0675. doi: 10.1634/theoncologist.2018-0675. [Epub ahead of print]

PMID:
31332100
3.

[Impact of the implementation of ICD-10 2016 version and Iris software on mortality statistics in Italy].

Orsi C, Navarra S, Frova L, Grande E, Marchetti S, Pappagallo M, Grippo F.

Epidemiol Prev. 2019 Mar-Jun;43(2-3):161-170. doi: 10.19191/EP19.2-3.P161.055. Italian.

PMID:
31293135
4.

The increase of sepsis-related mortality in Italy: a nationwide study, 2003-2015.

Grande E, Grippo F, Frova L, Pantosti A, Pezzotti P, Fedeli U.

Eur J Clin Microbiol Infect Dis. 2019 Sep;38(9):1701-1708. doi: 10.1007/s10096-019-03601-3. Epub 2019 Jun 11.

PMID:
31187308
5.

First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD).

Carrato A, Benavides M, Massutí B, Ferreiro-Monteagudo R, García Alfonso P, Falcó E, Reboredo M, Cano T, Gallego J, Viéitez JM, Layos L, Salud A, Polo E, Dotor E, Durán-Ogalla G, Rodriguez-Garrote M, Calvo A, Grande E, Aranda E.

BMC Cancer. 2019 Jun 3;19(1):533. doi: 10.1186/s12885-019-5753-7.

6.

On professionalism in the management of thyroid tumors and multidisciplinary working groups (reply letter).

Díez JJ, Galofré JC, Oleaga A, Grande E, Mitjavila M, Moreno P.

Endocrinol Diabetes Nutr. 2019 May 15. pii: S2530-0164(19)30108-9. doi: 10.1016/j.endinu.2019.03.012. [Epub ahead of print] English, Spanish. No abstract available.

PMID:
31103462
7.

Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys".

Alonso-Gordoa T, García-Bermejo ML, Grande E, Garrido P, Carrato A, Molina-Cerrillo J.

Int J Mol Sci. 2019 Apr 17;20(8). pii: E1901. doi: 10.3390/ijms20081901. Review.

8.

Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma.

Garcia-Carbonero R, Marquez-Rodas I, de la Cruz-Merino L, Martinez-Trufero J, Cabrera MA, Piulats JM, Capdevila J, Grande E, Martin-Algarra S, Berrocal A.

Oncologist. 2019 Apr 8. pii: theoncologist.2018-0718. doi: 10.1634/theoncologist.2018-0718. [Epub ahead of print]

PMID:
30962295
9.

Inhibition of Serotonin Synthesis May Have Antitumor Activity? Long-Term Efficacy in a Patient with Gastrointestinal Neuroendocrine Tumor.

Molina-Cerrillo J, Grande E, Alonso-Gordoa T.

Oncologist. 2019 Jul;24(7):e597-e599. doi: 10.1634/theoncologist.2018-0776. Epub 2019 Mar 15.

PMID:
30877189
10.

Pharmacokinetic Study of Osimertinib in Cancer Patients with Mild or Moderate Hepatic Impairment.

Grande E, Harvey RD, You B, Batlle JF, Galbraith H, Sarantopoulos J, Ramalingam SS, Mann H, So K, Johnson M, Vishwanathan K.

J Pharmacol Exp Ther. 2019 May;369(2):291-299. doi: 10.1124/jpet.118.255919. Epub 2019 Mar 14.

PMID:
30872388
11.

Economics of gastroenteropancreatic neuroendocrine tumors: a systematic review.

Grande E, Díaz Á, López C, Munarriz J, Reina JJ, Vera R, Bernárdez B, Aller J, Capdevila J, Garcia-Carbonero R, Jimenez Fonseca P, Trapero-Bertran M.

Ther Adv Endocrinol Metab. 2019 Feb 18;10:2042018819828217. doi: 10.1177/2042018819828217. eCollection 2019. Review.

12.

Correction to: SEOM clinical guideline for treatment of kidney cancer (2017).

Gallardo E, Méndez-Vidal MJ, Pérez-Gracia JL, Sepúlveda-Sánchez JM, Campayo M, Chirivella-González I, García-Del-Muro X, González-Del-Alba A, Grande E, Suárez C.

Clin Transl Oncol. 2019 May;21(5):692-693. doi: 10.1007/s12094-019-02058-2.

PMID:
30798511
13.

Results of a nationwide survey on multidisciplinary teams on thyroid cancer in Spain.

Díez JJ, Galofré JC, Oleaga A, Grande E, Mitjavila M, Moreno P.

Clin Transl Oncol. 2019 Feb 5. doi: 10.1007/s12094-019-02056-4. [Epub ahead of print]

PMID:
30721524
14.

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial.

Vink P, Delgado Mingorance I, Maximiano Alonso C, Rubio-Viqueira B, Jung KH, Rodriguez Moreno JF, Grande E, Marrupe Gonzalez D, Lowndes S, Puente J, Kristeleit H, Farrugia D, McNeil SA, Campora L, Di Paolo E, El Idrissi M, Godeaux O, López-Fauqued M, Salaun B, Heineman TC, Oostvogels L; Zoster-028 Study Group.

Cancer. 2019 Apr 15;125(8):1301-1312. doi: 10.1002/cncr.31909. Epub 2019 Feb 1.

PMID:
30707761
15.

The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG).

Font A, Luque R, Villa JC, Domenech M, Vázquez S, Gallardo E, Virizuela JA, Beato C, Morales-Barrera R, Gelabert A, Maciá S, Puente J, Rubio G, Maldonado X, Perez-Valderrama B, Pinto A, Fernández Calvo O, Grande E, Garde-Noguera J, Fernández-Parra E, Arranz JÁ.

Target Oncol. 2019 Feb;14(1):15-32. doi: 10.1007/s11523-019-00619-7.

PMID:
30694442
16.

Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib.

Jiménez-Fonseca P, Martín MN, Carmona-Bayonas A, Calvo A, Fernández-Mateos J, Redrado M, Capdevila J, Lago NM, Lacasta A, Muñarriz J, Segura Á, Fuster J, Barón F, Llanos M, Serrano R, Castillo A, Cruz Hernández JJ, Grande E.

Oncotarget. 2018 Dec 11;9(97):36894-36905. doi: 10.18632/oncotarget.26380. eCollection 2018 Dec 11.

17.

Characteristics of professionalism of specialists and advantages of multidisciplinary teams in thyroid cancer: results of a national opinion survey.

Díez JJ, Galofré JC, Oleaga A, Grande E, Mitjavila M, Moreno P.

Endocrinol Diabetes Nutr. 2019 Feb;66(2):74-82. doi: 10.1016/j.endinu.2018.10.009. Epub 2019 Jan 3. English, Spanish.

PMID:
30612901
18.

Corrigendum re: "Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens" [Eur Urol 2018;73:462-8].

Perez-Gracia JL, Loriot Y, Rosenberg JE, Powles T, Necchi A, Hussain SA, Morales-Barrera R, Retz MM, Niegisch G, Durán I, Théodore C, Grande E, Shen X, Wang J, Nelson B, Derleth CL, van der Heijden MS.

Eur Urol. 2019 Mar;75(3):e82-e83. doi: 10.1016/j.eururo.2018.11.032. Epub 2018 Nov 28. No abstract available.

PMID:
30502102
19.

A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours.

Schram AM, Gandhi L, Mita MM, Damstrup L, Campana F, Hidalgo M, Grande E, Hyman DM, Heist RS.

Br J Cancer. 2018 Dec;119(12):1471-1476. doi: 10.1038/s41416-018-0322-4. Epub 2018 Nov 14.

PMID:
30425349
20.

Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial.

Gross-Goupil M, Kwon TG, Eto M, Ye D, Miyake H, Seo SI, Byun SS, Lee JL, Master V, Jin J, DeBenedetto R, Linke R, Casey M, Rosbrook B, Lechuga M, Valota O, Grande E, Quinn DI.

Ann Oncol. 2018 Dec 1;29(12):2371-2378. doi: 10.1093/annonc/mdy454.

21.

Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours.

Barriuso J, Custodio A, Afonso R, Alonso V, Astudillo A, Capdevila J, García-Carbonero R, Grande E, Jimenez-Fonseca P, Marazuela M, Rodríguez-Antona C, Aller J.

Cancer Treat Rev. 2018 Nov;70:209-222. doi: 10.1016/j.ctrv.2018.09.008. Epub 2018 Sep 26. Review.

PMID:
30292979
22.

Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma.

Powles T, Motzer RJ, Escudier B, Pal S, Kollmannsberger C, Pikiel J, Gurney H, Rha SY, Park SH, Geertsen PF, Gross-Goupil M, Grande E, Suarez C, Markby DW, Arroyo A, Dean M, Choueiri TK, George D.

Br J Cancer. 2018 Sep;119(6):663-669. doi: 10.1038/s41416-018-0164-0. Epub 2018 Sep 10.

PMID:
30197417
23.

Sepsis as a Cause of Infectious Disease Mortality.

Fedeli U, Grande E.

JAMA. 2018 Aug 28;320(8):836-837. doi: 10.1001/jama.2018.7941. No abstract available.

PMID:
30167688
24.

Excess mortality related to circulatory system diseases and diabetes mellitus among Italian AIDS patients vs. non-AIDS population: a population-based cohort study using the multiple causes-of-death approach.

Suligoi B, Virdone S, Taborelli M, Frova L, Grande E, Grippo F, Pappagallo M, Regine V, Pugliese L, Serraino D, Zucchetto A.

BMC Infect Dis. 2018 Aug 28;18(1):428. doi: 10.1186/s12879-018-3336-x.

25.

Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer.

Capdevila J, Newbold K, Licitra L, Popovtzer A, Moreso F, Zamorano J, Kreissl M, Aller J, Grande E.

Cancer Treat Rev. 2018 Sep;69:164-176. doi: 10.1016/j.ctrv.2018.06.019. Epub 2018 Jul 2. Review.

PMID:
30032061
26.

Consensus document on the progression and treatment response criteria in gastroenteropancreatic neuroendocrine tumors.

Merino-Casabiel X, Aller J, Arbizu J, García-Figueiras R, González C, Grande E, Jiménez-Fonseca P, Sevilla MI, Capdevila J.

Clin Transl Oncol. 2018 Dec;20(12):1522-1528. doi: 10.1007/s12094-018-1881-9. Epub 2018 May 15.

27.

Consents or waivers of responsibility? Parents' information in NICU.

Bellieni CV, Coradeschi C, Curcio MR, Grande E, Buonocore G.

Minerva Pediatr. 2018 May 14. doi: 10.23736/S0026-4946.18.05084-3. [Epub ahead of print]

PMID:
29756697
28.

Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome.

Weickert MO, Kaltsas G, Hörsch D, Lapuerta P, Pavel M, Valle JW, Caplin ME, Bergsland E, Kunz PL, Anthony LB, Grande E, Öberg K, Welin S, Lombard-Bohas C, Ramage JK, Kittur A, Yang QM, Kulke MH.

Clin Ther. 2018 Jun;40(6):952-962.e2. doi: 10.1016/j.clinthera.2018.04.006. Epub 2018 May 1.

29.

Inconclusive Analysis of the Connection Between Secondary Hematologic Malignancies and Radioiodine Treatment.

Kreissl MC, Grande E.

J Clin Oncol. 2018 Jun 20;36(18):1882-1883. doi: 10.1200/JCO.2018.78.1054. Epub 2018 May 3. No abstract available.

PMID:
29723089
30.

[Nutritional support and parenteral nutrition in the oncological patient: an expert group consensus report].

Camblor-Álvarez M, Ocón-Bretón MJ, Luengo-Pérez LM, Viruzuela JA, Sendrós-Maroño MJ, Cervera-Peris M, Grande E, Álvarez-Hernández J, Jiménez-Fonseca P.

Nutr Hosp. 2018 Jan 10;35(1):224-233. doi: 10.20960/nh.1361. Review. Spanish.

31.

Huge recurrent gastric neuroendocrine tumor: a second-line chemotherapeutic dilemma.

Ribeiro MJM, Alonso T, Gajate P, Molina J, Barquin A, Perna C, Grande E.

Autops Case Rep. 2018 Feb 27;8(1):e2018005. doi: 10.4322/acr.2018.005. eCollection 2018 Jan-Mar.

32.

Antiepileptic drugs: Role in paediatric poisoning.

Ferranti S, Grande E, Gaggiano C, Grosso S.

J Paediatr Child Health. 2018 May;54(5):475-479. doi: 10.1111/jpc.13833. Epub 2018 Jan 2. Review.

PMID:
29292550
33.

Nutritional support and parenteral nutrition in cancer patients: An expert consensus report.

Ocón Bretón MJ, Luengo Pérez LM, Virizuela JA, Álvarez Hernández J, Jiménez Fonseca P, Cervera Peris M, Sendrós Madroño MJ, Grande E, Camblor Álvarez M.

Endocrinol Diabetes Nutr. 2018 Mar;65 Suppl 1:17-23. doi: 10.1016/j.endinu.2017.10.012. Epub 2017 Dec 29. English, Spanish.

PMID:
29292219
34.

Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens.

Perez-Gracia JL, Loriot Y, Rosenberg JE, Powles T, Necchi A, Hussain SA, Morales-Barrera R, Retz MM, Niegisch G, Durán I, Théodore C, Grande E, Shen X, Wang J, Nelson B, Derleth CL, van der Heijden MS.

Eur Urol. 2017 Dec 19. pii: S0302-2838(17)31015-1. doi: 10.1016/j.eururo.2017.11.023. [Epub ahead of print] Erratum in: Eur Urol. 2019 Mar;75(3):e82-e83.

PMID:
29273410
35.

Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors.

Salazar R, Garcia-Carbonero R, Libutti SK, Hendifar AE, Custodio A, Guimbaud R, Lombard-Bohas C, Ricci S, Klümpen HJ, Capdevila J, Reed N, Walenkamp A, Grande E, Safina S, Meyer T, Kong O, Salomon H, Tavorath R, Yao JC.

Oncologist. 2018 Jul;23(7):766-e90. doi: 10.1634/theoncologist.2017-0144. Epub 2017 Dec 14.

36.

SEOM clinical guideline for treatment of kidney cancer (2017).

Gallardo E, Méndez-Vidal MJ, Pérez-Gracia JL, Sepúlveda-Sánchez JM, Campayo M, Chirivella-González I, García-Del-Muro X, González-Del-Alba A, Grande E, Suárez C.

Clin Transl Oncol. 2018 Jan;20(1):47-56. doi: 10.1007/s12094-017-1765-4. Epub 2017 Nov 13. Erratum in: Clin Transl Oncol. 2019 May;21(5):692-693.

37.

Prognostic and predictive role of the PI3K-AKT-mTOR pathway in neuroendocrine neoplasms.

Gajate P, Alonso-Gordoa T, Martínez-Sáez O, Molina-Cerrillo J, Grande E.

Clin Transl Oncol. 2018 May;20(5):561-569. doi: 10.1007/s12094-017-1758-3. Epub 2017 Nov 9. Review.

PMID:
29124519
38.

Nutritional support and parenteral nutrition in cancer patients: an expert consensus report.

Virizuela JA, Camblor-Álvarez M, Luengo-Pérez LM, Grande E, Álvarez-Hernández J, Sendrós-Madroño MJ, Jiménez-Fonseca P, Cervera-Peris M, Ocón-Bretón MJ.

Clin Transl Oncol. 2018 May;20(5):619-629. doi: 10.1007/s12094-017-1757-4. Epub 2017 Oct 17. Review.

PMID:
29043569
39.

HIF pathway and c-Myc as biomarkers for response to sunitinib in metastatic clear-cell renal cell carcinoma.

Maroto P, Esteban E, Parra EF, Mendez-Vidal MJ, Domenech M, Pérez-Valderrama B, Calderero V, Pérez-Gracia JL, Grande E, Algaba F.

Onco Targets Ther. 2017 Sep 20;10:4635-4643. doi: 10.2147/OTT.S137677. eCollection 2017.

40.

Comparison of Health and Risk Factors of Older, Working-age Australians, Italians and Italian-born Migrants to Australia, with Data from an Italian (PASSI), and an Australian (SAMSS) Risk Factor Surveillance System.

Taylor AW, Grande ED, Fateh-Moghadam P, Montgomerie A, Battisti L, Barrie H, Kourbelis C, Campostrini S.

J Immigr Minor Health. 2018 Oct;20(5):1190-1196. doi: 10.1007/s10903-017-0654-9.

41.

Recommendations on managing lenvatinib and everolimus in patients with advanced or metastatic renal cell carcinoma.

Grande E, Glen H, Aller J, Argenziano G, Lamas MJ, Ruszniewski P, Zamorano JL, Edmonds K, Sarker S, Staehler M, Larkin J.

Expert Opin Drug Saf. 2017 Dec;16(12):1413-1426. doi: 10.1080/14740338.2017.1380624. Epub 2017 Sep 28. Review.

PMID:
28920492
42.

Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors.

Carmona-Bayonas A, Jiménez-Fonseca P, Custodio A, Grande E, Capdevila J, López C, Teule A, Garcia-Carbonero R; Spanish Neuroendocrine Tumor Group (GETNE).

Curr Oncol Rep. 2017 Sep 18;19(11):72. doi: 10.1007/s11912-017-0633-2. Review.

PMID:
28920153
43.

Novel concepts for initiating multitargeted kinase inhibitors in radioactive iodine refractory differentiated thyroid cancer.

Tuttle RM, Brose MS, Grande E, Kim SW, Tahara M, Sabra MM.

Best Pract Res Clin Endocrinol Metab. 2017 Jun;31(3):295-305. doi: 10.1016/j.beem.2017.04.014. Epub 2017 May 12. Review.

44.

Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.

de Bono JS, Chowdhury S, Feyerabend S, Elliott T, Grande E, Melhem-Bertrandt A, Baron B, Hirmand M, Werbrouck P, Fizazi K.

Eur Urol. 2018 Jul;74(1):37-45. doi: 10.1016/j.eururo.2017.07.035. Epub 2017 Aug 23.

45.

Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC).

Capdevila J, Trigo JM, Aller J, Manzano JL, Adrián SG, Llopis CZ, Reig Ò, Bohn U, Cajal TRY, Duran-Poveda M, Astorga BG, López-Alfonso A, Martínez JM, Porras I, Reina JJ, Palacios N, Grande E, Cillán E, Matos I, Grau JJ.

Eur J Endocrinol. 2017 Oct;177(4):309-317. doi: 10.1530/EJE-17-0243. Epub 2017 Jul 7.

PMID:
28687563
46.

Emerging use of everolimus in the treatment of neuroendocrine tumors.

Gajate P, Martínez-Sáez O, Alonso-Gordoa T, Grande E.

Cancer Manag Res. 2017 Jun 20;9:215-224. doi: 10.2147/CMAR.S113382. eCollection 2017. Review.

47.

Bruton's tyrosine kinase (BTK) as a promising target in solid tumors.

Molina-Cerrillo J, Alonso-Gordoa T, Gajate P, Grande E.

Cancer Treat Rev. 2017 Jul;58:41-50. doi: 10.1016/j.ctrv.2017.06.001. Epub 2017 Jun 9. Review.

PMID:
28641100
48.

Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies.

Castellano D, Maroto JP, Espinosa E, Grande E, Bolós MV, Llinares J, Esteban E, González Del Alba A, Climent MA, Arranz JA, Méndez MJ, Fernández Parra E, Antón-Aparicio L, Bayona C, Gallegos I, Gallardo E, Samaniego L, García Donas J.

Expert Opin Drug Saf. 2018 Jun;17(6):573-579. doi: 10.1080/14740338.2017.1330410. Epub 2017 Aug 28.

PMID:
28535693
49.

Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting.

Puente J, Grande E, Medina A, Maroto P, Lainez N, Arranz JA.

Ther Adv Med Oncol. 2017 May;9(5):307-318. doi: 10.1177/1758834017692779. Epub 2017 Mar 1. Review.

50.

Multiple cause-of-death data among people with AIDS in Italy: a nationwide cross-sectional study.

Grande E, Zucchetto A, Suligoi B, Grippo F, Pappagallo M, Virdone S, Camoni L, Taborelli M, Regine V, Serraino D, Frova L.

Popul Health Metr. 2017 May 18;15(1):19. doi: 10.1186/s12963-017-0135-3.

Supplemental Content

Loading ...
Support Center